H. Iv Vaccine Research Paper

Our Search To The Discovery of the H.I.V Vaccine and

The Safest and Effective Solution to Execute

Nathan Mousa

Saddleback College

Abstract This research paper will explore the past attempts of developing a safe and efficient vaccine for the human immunodeficiency virus (H.I.V) illustrating the failures of the multiple methods including STEP study, Antibodies, and T-Cells. However the paper will explain what was to be learned from each trial and how it improved future methods. The paper will also describe the downfall of the field since the 2007 STEP study program and how inspiration was later reignited with the RV144 trials. Where we’re at currently with an H.I.V vaccine will be explained and what we could do to improve

Over the past years we have seen many attempts and trials come and go yet we still have no indication on a proper, safe, and effective vaccine. In 2007 we had the STEP study, also known as the Merck trial, and learned that it failed miserably and not only did it fail but it also casted a shadow over the field that many scientists and funding companies did not want to deal with because it increased the risk of candidates to receive the H.I.V virus. Since then we’ve seen many trial and errors with different types of vaccines. The RV144 trial that took place in Thailand inspired once again that we can find a solution to combating H.I.V and neutralize the virus once and for all. With many different policies, programs, and education we have been able to lower the H.I.V % infected yearly but still the number remains high up to 2.7 million a year being infected leaving us at a total of 34 million infected worldwide. Recent reports suggest that a proper vaccine for H.I.V will be here by 2019 but many promises have been made before so we’ll have to see when the time comes.

References

Andersson, K. M., Paltiel, A. D., & Owens, D. K. (2011). The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in southern africa: Examining

Nature,

682-687.

Li, S. S., Gilbert, P. B., Tomaras, G. D., Kijak, G., Ferrari, G., Thomas, R., . . . Geraghty, D. E.

(2014). FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. Journal of Clinical Investigation, 124(9), 3879-90.

Martin, A., & Scharff, M. D. (2001). Antibody alterations. Nature, 412(6850), 870-871.

Munier, C. L., Andersen, C. R., & Kelleher, A. D. (2011). H.I.V Vaccines: Progress to Date.

Drugs, 71(4), 387-414 28p.

Williams, K. C., & Burdo, T. H. (2009). H.I.V and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. Apmis, 117(5/6), 400-412.

Robb, M. L. (2008). Failure of the merck H.I.V vaccine: An uncertain step forward. The Lancet,

372(9653), 1857-8.

Rowland-Jones, S., & Dong, T. (2006). H.I.V: Tired T cells turn around. Nature, 443(7109),

282-3.

Sachs, J. S. (2008). REBOOTING THE AIDS VACCINE. Popular Science, 272(1), 27-29.

Weatherall, C. J. (2009). Trials and tribulations of H.I.V vaccines. H.I.V Therapy, 3(2), 145-160.

H.I.V/AIDS; why so many antibodies fail to protect against H.I.V infection. (2010). AIDS Vaccine Week, ,